
High-THC Leads Growth as Australia Tightens TGA Prescribing Rules
The medical cannabis industries in Australia and New Zealand are continuing to evolve rapidly, with both markets showing signs of

The medical cannabis industries in Australia and New Zealand are continuing to evolve rapidly, with both markets showing signs of

Australia’s thriving medical cannabis industry has continued its blistering levels of growth, seeing the amount of medical cannabis imported grow

Germany’s Ministry of Health has now published a long-feared draft amendment to its Medical Cannabis Act (MedCanG), threatening a crackdown which will be a major cause for concern for hundreds of cannabis businesses, both in and outside of German borders.

Ahead of the Cannabis Europa 2026, which kicks off next Tuesday (June 24) at the Barbican Centre, we caught up with Eidan Havas, the Founder of one of Australia’s leading medical cannabis product wholesalers, The Entourage Effect.

Medical cannabis clinics are often driven to scale their operations quickly, out of a desire to reach more patients who could benefit from treatment and the need to remain affordable for them. But doing so shouldn’t come at the cost of regulatory compliance.

Australia’s medical cannabis market is thriving, with revenues expected to grow from around US$600m in 2024 to more than US$1.2bn by 2028, according to Prohibition Partners’ Global Cannabis Report: 5th Edition.

In response to this growing exodus of promising biotech firms, the European Union has proposed a new Biotech Act, as part of ongoing efforts by the European Commission to strengthen the continent’s biotechnology and biomanufacturing sectors, which have struggled with fragmented rules and sluggish approval processes.

UK-based cannabinoid pharmaceutical company Ananda Pharma has received ethics approval for a Phase 1 clinical study for its lead compound in Australia.

According to Prohibition Partners’ new Global Cannabis Report: 5th Edition, launching today, Australia’s medical cannabis revenues are expected to grow from around US$600m in 2024 to more than US$1.2bn by 2028.

Australia and New Zealand are undergoing contrasting reforms in their medical cannabis regulations. New Zealand aims to lower product quality
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
© 2023 Prohibition Holdings Ltd. All Rights Reserved.